Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Related Videos
View All
Related Content